Osteogenic sarcoma with clinically detectable metastasis at initial presentation.

Meyers, Paul A.; Heller, Glenn; Healey, John H.; Huvos, Andrew G.; Applewhite, Ann; Sun, Ming Hsi; LaQuaglia, Michael P.

doi:10.1200/jco.1993.11.3.449

Cited by 354 publications

(259 citation statements)

References 5 publications

Supporting

Mentioning

240

Contrasting

Unclassified

Order By: Relevance

“…The 5 year OS for patients who had metastasis during follow up is 30-50% and 0% for patients who had metastasis at initial diagnosis (Clark et al, 2008;Ritter and Bielack, 2010;He et al, 2013). In the study of Meyers et al the 2 year OS for metastatic patients were 11% (Meyers et al, 1993). In the present study the PFS and OS for metastatic patients were 2 and 4 months, respectively.…”

Section: Discussionsupporting

confidence: 46%

Clinicopathologic Features and Prognosis of Osteosarcoma in Turkish Adults

Şeker

Şeker²,

Aksoy³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Osteosarcomas are the most common solid malignancies of bone. In the last two decades there have been no concrete developments in their systemic treatment. In this trial we aimed to present our osteosarcoma patient clinical and demographic outcomes. Materials and Methods: Patients treated and followed up for osteosarcoma in Ankara Numune Education and Research Hospital from 2002 to 2012 were reviewed retrospectively. Results: A total of 21 patients (15 male, 6 female) were diagnosed with osteosarcoma. The disease was located at extremities in 76% and in 14% was metastatic at the time of diagnosis. Median disease free survival (DFS) was 36 months in non-metastatic patients and median progression free survival (PFS) was 2 months in metastatic patients (p<0.0001). Median overall survival (OS) was 80 months and 4 months, respectively (p=0.012). There were no survival differences in terms of presentation with pathological fracture, tumor size, tumor grade, alkaline phosphatase and lactate dehydrogenase level and type of chemotherapy regimen. Conclusions: Tumor site and stages are the most important prognostic factors for osteosarcoma. Extremity primary tumors have beter survival rates than non-extremity tumors. As a result of the use of effective chemotherapy the long term survival rates have improved from 10-20% to 60-70% in the last decades but we need more active agents, especially for metastatic cases.

show abstract

Section: Discussionsupporting

confidence: 46%

Clinicopathologic Features and Prognosis of Osteosarcoma in Turkish Adults

Şeker

Şeker²,

Aksoy³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Research has been focused on identifying reliable prognostic factors. Axial lesions have an inferior outcome [35,36] and the presence of clinically detectable primary metastatic disease correlates with poor prognosis [35,37]. Protein expression in serum, such as levels of LDH or alkaline phosphatase correlate with outcome [1,38] and other molecular markers are also being investigated to determine the relative significance for predicting prognosis [39,40].…”

Section: Discussionmentioning

confidence: 99%

Antisense inhibition of hyaluronan synthase-2 in human osteosarcoma cells inhibits hyaluronan retention and tumorigenicity

Nishida

Knudson

et al. 2005

Experimental Cell Research

View full text Add to dashboard Cite

Osteosarcoma is a common malignant bone tumor associated with childhood and adolescence. The results of numerous studies have suggested that hyaluronan plays an important role in regulating the aggressive behavior of various types of cancer cells. However, no studies have addressed hyaluronan with respect to osteosarcomas. In this investigation, the mRNA expression copy number of three mammalian hyaluronan synthases (HAS) was determined using competitive RT-PCR in the osteoblastic osteosarcoma cell line, MG-63. MG-63 are highly malignant osteosarcoma cells with an abundant hyaluronan-rich matrix. The results demonstrated that HAS-2 is the predominant HAS in MG-63. Accumulation of intracellular hyaluronan increased in association with the proliferative phase of these cells. The selective inhibition of HAS-2 mRNA in MG-63 cells by antisense phosphorothioate oligonucleotides resulted in reduced hyaluronan accumulation by these cells. As expected, the reduction in hyaluronan disrupted the assembly of cell-associated matrices. However, of most interest, coincident with the reduction in hyaluronan, there was a substantial decrease in cell proliferation, a decrease in cell motility and a decrease in cell invasiveness. These data suggest that hyaluronan synthesized by HAS-2 in MG-63 plays a crucial role in osteosarcoma cell proliferation, motility and invasion.

show abstract

“…The presence of clinically detectable metastatic disease confers an unfavourable prognosis. 6 Death from osteosarcoma is usually the result of progressive lung metastasis with respiratory failure secondary to widespread disease. 7 Radiography, CT, structural and functional MRI, Doppler sonography, and 99mTc scintigraphy have been used to estimate the tumour size in onedimension (tumour length or tumour diameter), 2-dimension (tumour plane), or 3-dimension (tumour volume).…”

Section: Figurementioning

confidence: 99%

Tumour Volume and Lung Metastasis in Patients with Osteosarcoma

Munajat

Zulmi

Nor-Azman

et al. 2008

J Orthop Surg (Hong Kong)

View full text Add to dashboard Cite

Purpose. To assess the association between tumour volume and occurrence of lung metastasis in patients with osteosarcoma and to determine the cut-off value. Methods.Records of 70 patients with histopathologically confirmed primary osteosarcoma in the extremities who had magnetic resonance imaging and computed tomography of the thorax less than one month before treatment were reviewed, with reference to the official report of tumour dimensions and lung metastasis by radiologists. The status of lung metastasis was assessed. Tumour volume was measured using the formula for an ellipsoidal mass. Results. Of the 70 patients with osteosarcoma, 33 (47%) had evidence of lung metastasis. Tumour volume was directly associated with occurrence of lung metastasis (p=0.048). The proportion having lung metastasis when the primary tumour volume exceeded 371 cm 3 was 69%, compared to 34% in those with smaller tumours. Conclusion. Larger tumours are more likely to

show abstract

Osteogenic sarcoma with clinically detectable metastasis at initial presentation.

Cited by 354 publications

References 5 publications

Clinicopathologic Features and Prognosis of Osteosarcoma in Turkish Adults

Clinicopathologic Features and Prognosis of Osteosarcoma in Turkish Adults

Antisense inhibition of hyaluronan synthase-2 in human osteosarcoma cells inhibits hyaluronan retention and tumorigenicity

Tumour Volume and Lung Metastasis in Patients with Osteosarcoma

Contact Info

Product

Resources

About